Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.
J Clin Invest. 2021 05 17; 131(10)JCI

Abstract

Recent studies have shown T cell cross-recognition of SARS-CoV-2 and common cold coronavirus spike proteins. However, the effect of SARS-CoV-2 vaccines on T cell responses to common cold coronaviruses (CCCs) remains unknown. In this study, we analyzed CD4+ T cell responses to spike peptides from SARS-CoV-2 and 3 CCCs (HCoV-229E, HCoV-NL63, and HCoV-OC43) before and after study participants received Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) mRNA-based COVID-19 vaccines. Vaccine recipients showed broad T cell responses to the SARS-CoV-2 spike protein, and we identified 23 distinct targeted peptides in 9 participants, including 1 peptide that was targeted in 6 individuals. Only 4 of these 23 targeted peptides would potentially be affected by mutations in the UK (B.1.1.7) and South African (B.1.351) variants, and CD4+ T cells from vaccine recipients recognized the 2 variant spike proteins as effectively as they recognized the spike protein from the ancestral virus. Interestingly, we observed a 3-fold increase in the CD4+ T cell responses to HCoV-NL63 spike peptides after vaccination. Our results suggest that T cell responses elicited or enhanced by SARS-CoV-2 mRNA vaccines may be able to control SARS-CoV-2 variants and lead to cross-protection against some endemic coronaviruses.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial Protocol
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

33822770

Citation

Woldemeskel, Bezawit A., et al. "SARS-CoV-2 mRNA Vaccines Induce Broad CD4+ T Cell Responses That Recognize SARS-CoV-2 Variants and HCoV-NL63." The Journal of Clinical Investigation, vol. 131, no. 10, 2021.
Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J Clin Invest. 2021;131(10).
Woldemeskel, B. A., Garliss, C. C., & Blankson, J. N. (2021). SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. The Journal of Clinical Investigation, 131(10). https://doi.org/10.1172/JCI149335
Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA Vaccines Induce Broad CD4+ T Cell Responses That Recognize SARS-CoV-2 Variants and HCoV-NL63. J Clin Invest. 2021 05 17;131(10) PubMed PMID: 33822770.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. AU - Woldemeskel,Bezawit A, AU - Garliss,Caroline C, AU - Blankson,Joel N, PY - 2021/03/08/received PY - 2021/03/31/accepted PY - 2021/08/17/pmc-release PY - 2021/4/7/pubmed PY - 2021/5/26/medline PY - 2021/4/6/entrez KW - COVID-19 KW - T cells JF - The Journal of clinical investigation JO - J Clin Invest VL - 131 IS - 10 N2 - Recent studies have shown T cell cross-recognition of SARS-CoV-2 and common cold coronavirus spike proteins. However, the effect of SARS-CoV-2 vaccines on T cell responses to common cold coronaviruses (CCCs) remains unknown. In this study, we analyzed CD4+ T cell responses to spike peptides from SARS-CoV-2 and 3 CCCs (HCoV-229E, HCoV-NL63, and HCoV-OC43) before and after study participants received Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) mRNA-based COVID-19 vaccines. Vaccine recipients showed broad T cell responses to the SARS-CoV-2 spike protein, and we identified 23 distinct targeted peptides in 9 participants, including 1 peptide that was targeted in 6 individuals. Only 4 of these 23 targeted peptides would potentially be affected by mutations in the UK (B.1.1.7) and South African (B.1.351) variants, and CD4+ T cells from vaccine recipients recognized the 2 variant spike proteins as effectively as they recognized the spike protein from the ancestral virus. Interestingly, we observed a 3-fold increase in the CD4+ T cell responses to HCoV-NL63 spike peptides after vaccination. Our results suggest that T cell responses elicited or enhanced by SARS-CoV-2 mRNA vaccines may be able to control SARS-CoV-2 variants and lead to cross-protection against some endemic coronaviruses. SN - 1558-8238 UR - https://www.unboundmedicine.com/medline/citation/33822770/SARS_CoV_2_mRNA_vaccines_induce_broad_CD4+_T_cell_responses_that_recognize_SARS_CoV_2_variants_and_HCoV_NL63_ L2 - https://doi.org/10.1172/JCI149335 DB - PRIME DP - Unbound Medicine ER -